RecruitingNot ApplicableNCT01977274
Predictive Clinical and Biological Parameters in Gynecological Cancer
Predictive Clinical and Biological Parameters in Gynecological Cancer - GC-BIO-IPC 2013-010
Sponsor
Institut Paoli-Calmettes
Enrollment
300 participants
Start Date
Dec 1, 2013
Study Type
INTERVENTIONAL
Conditions
Summary
Research of predictive clinical and biological factors in breast cancer : genomic, proteomic, mutation
Eligibility
Sex: FEMALEMin Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is collecting blood, tissue, and imaging information from women with gynecologic cancers (such as ovarian, uterine, or cervical cancer) to identify biological markers that can predict how well a patient will respond to treatment.
**You may be eligible if...**
- You have been diagnosed with a gynecologic cancer (ovarian, fallopian tube, uterine, cervical, or vaginal cancer)
- You are scheduled for surgery or biopsy as part of your cancer treatment or diagnosis
- You are willing to allow the collection of blood and tissue samples at multiple points during treatment
- You are at least 18 years old
**You may NOT be eligible if...**
- You are unable to give informed consent
- You are pregnant
- You are receiving treatment at a facility not participating in the study
- You have another active cancer that may interfere with the study results
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERgynecological cancer
blood and tumor samples
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT01977274
Related Trials
Identifying Genetic Targets in Gynecological Tumors
NCT071693961 location
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
NCT0654594218 locations
IDOV-Immune for Advanced Solid Tumors
NCT069106575 locations
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
NCT056361111 location
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT0579716860 locations